MATERIALS AND METHODS: This theoretical study includes 20 patients previously treated for prostate cancer using external beam radiotherapy. All patients had a Nickel-Titanium (Ni-Ti) stent inserted into the prostate part of urethra. The stent has been used during the treatment course as an internal marker for patient positioning prior to treatment. In this study the stent is used for delineating urethra while intensity modulated radiotherapy was used for lowering dose to urethra. Evaluation of the dose plans were performed using a tumour control probability model based on the concept of uniform equivalent dose.
RESULTS: The feasibility of the urethra dose reduction method is validated and a reduction of about 17% is shown to be possible. Calculations suggest a nearly preserved tumour control probability.
CONCLUSIONS: A new concept for urethra dose reduction is presented. The method relies on the use of a Ni-Ti stent as a fiducial marker combined with intensity modulated radiotherapy. Theoretical calculations suggest preserved tumour control.
Written by:
Thomsen JB, Arp DT, Carl J. Are you the author?
Department of Medical Physics, Oncology, Aalborg Sygehus, Aarhus University Hospital, Denmark.
Reference: Radiother Oncol. 2011 Dec 23. Epub ahead of print.
doi: 10.1016/j.radonc.2011.11.015
PubMed Abstract
PMID: 22197354
UroToday.com Prostate Cancer Section
